Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28681518 | 0.84 | CA2 (0.52) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL5820354 | 0.82 | ALDH1A1 (0.53) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL4422390 | 0.80 | CA2 (0.48) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL28185945 | 0.79 | CA2 (0.46) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL6522199 | 0.79 | ALDH1A1 (0.50) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL27087396 | 0.77 | CA2 (0.50) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL18486478 | 0.77 | SRC (0.45) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL3633797 | 0.76 | CA2 (0.48) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL15648979 | 0.76 | CFTR (0.48) | CA2CA4CA5AALDH1A1L3MBTL1 | |
| SCHEMBL7617570 | 0.76 | ALDH1A1 (0.47) | CA2CA4CA5AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120091917-A | Method for producing laminate, inkjet ink, and image recording method | 富士胶片株式会社 | 2025-06-03 | — | — | CN | disclosed |
| CN-119968271-A | Method for producing laminate, inkjet ink, and image recording method | 富士胶片株式会社 | 2025-05-09 | — | — | CN | disclosed |
| US-20240166808-A1 | Catalyst Composition For A Polyester Manufacturing Process | CLARIANT INTERNATIONAL LTD (CH) | 2024-05-23 | — | — | US | disclosed |
| CN-116715698-A | Preparation method of 6-phosphoryl 1,2, 4-triazine-3, 5 (2H, 4H) -diketone derivative | 河北工业大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-112778511-B | Catalyst composition for polyester production process | 科莱恩塑料和涂料有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20210214491-A1 | CATALYST COMPOSITION FOR A POLYESTER MANUFACTURING PROCESS | CLARIANT PLASTICS & COATINGS LTD (CH) | 2021-07-15 | — | — | US | disclosed |
| CN-112778511-A | Catalyst composition for polyester production process | 科莱恩塑料和涂料有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-10982045-B2 | Catalyst composition for a polyester manufacturing process | CLARIANT PLASTICS & COATINGS LTD (CH) | 2021-04-20 | — | — | US | disclosed |
| CN-107075097-B | Catalyst composition for polyester production process | 科莱恩塑料和涂料有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3000835-B1 | CATALYST COMPOSITION FOR A POLYESTER MANUFACTURING PROCESS | CLARIANT INT LTD (CH) | 2020-11-25 | — | — | EP | disclosed |
| EP-3131145-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | Toray Industries, Inc. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| CN-106165175-A | High molecular electrolyte composition and use its polyelectrolyte membrane, film electrode composite element and polymer electrolyte fuel cell | 东丽株式会社 | 2016-11-23 | — | — | CN | disclosed |
| WO-2016045923-A1 | CATALYST COMPOSITION FOR A POLYESTER MANUFACTURING PROCESS | CLARIANT INTERNATIONAL LTD (CH) | 2016-03-31 | — | — | WO | disclosed |
| EP-3000835-A1 | Catalyst composition for a polyester manufacturing process | Clariant International Ltd. (CH) | 2016-03-30 | — | — | EP | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-0549073-B1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI SA (FR) | 1997-03-26 | — | — | EP | disclosed |
| US-5296496-A | Treating degenerative diseases | STERLING WINTHROP INC. (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0549073-A1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | CA2 4076/4885CA4 4440/4885CA5A 4661/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | CA2 3626/4885CA4 3665/4885CA5A 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.